Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12387975 | 0.85 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL1848217 | 0.84 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL30787029 | 0.84 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL1172365 | 0.84 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL8215750 | 0.84 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL13730896 | 0.84 | CA12 (0.50) | PTGS2PTGS1ENPP2 | |
| SCHEMBL2319684 | 0.84 | EPAS1 (0.49) | PTGS2 | |
| SCHEMBL30488772 | 0.84 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL10193783 | 0.80 | PTGS1 (0.48) | PTGS2PTGS1 | |
| SCHEMBL15290561 | 0.80 | FABP3 (0.37) | PTGS2PTGS1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390625-A | Preparation method of 1- (aryl sulfonyl) bicyclo [1.1.0] butane compound | 苏州百灵威超精细材料有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118738567-A | Electrolyte and lithium ion battery | 惠州亿纬锂能股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| CN-108715590-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190229372-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10333172-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10290901-B2 | — | — | 2019-05-14 | — | — | US | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6872717-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| EP-1263720-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | PTGS2 2236/4885PTGS1 1002/4885ENPP2 2392/4885 |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | PTGS2 1099/4885PTGS1 1021/4885ENPP2 1078/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | PTGS2 1099/4885PTGS1 1021/4885ENPP2 1078/4885 |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | CHRM2, ACHE, DRD2 | PTGS2 1220/4885PTGS1 1359/4885ENPP2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.